Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOVUNA vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
FDA-approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
400 mg orally once daily with food.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19; undergoes oxidative metabolism to form hydroxy and carboxylic acid metabolites.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
98% bound to albumin.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
0.15 L/kg; indicates limited extravascular distribution, consistent with high plasma protein binding.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Oral: 85%.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
Child-Pugh A: No adjustment. Child-Pugh B: 200 mg orally once daily. Child-Pugh C: Not recommended.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Weight-based: ≥40 kg: 400 mg orally once daily; <40 kg: Not approved.
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment; monitor renal function due to age-related decline.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
None.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Potential for next-day impairment (e.g., drowsiness, impaired driving), risk of CNS depression, complex sleep behaviors (e.g., sleep-driving), risk of worsening depression or suicidal thoughts, caution in patients with a history of substance abuse.
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or strong CYP3A4 inducers (e.g., rifampin); patients with narcolepsy.
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Avoid grapefruit and grapefruit juice; take with or without food but consistently.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Based on animal studies, SOVUNA (antiviral agent) is associated with increased fetal loss and skeletal anomalies at maternal toxic doses in rodents and rabbits. In humans, data are insufficient to define a precise teratogenic risk. First trimester exposure does not show a clear pattern of major congenital malformations, but potential risks cannot be excluded. Second and third trimester exposure: no specific fetal adverse effects reported in limited human studies, but caution is advised due to possible placental transfer and unknown fetal effects.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
It is not known whether SOVUNA is excreted in human breast milk. Animal studies show excretion in milk. Due to potential adverse effects in nursing infants, breastfeeding during treatment is not recommended. M/P ratio is unknown.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No specific dosing adjustments are required during pregnancy based on available pharmacokinetic data. However, due to physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism), monitoring of clinical response and tolerance is recommended. No dose adjustment is recommended for standard antiviral dosing.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Monitor hepatic function closely due to potential hepatotoxicity; assess renal function before initiation; avoid in patients with severe hepatic impairment (Child-Pugh C).
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take exactly as prescribed; do not stop without consulting your doctor.,Report any signs of liver problems: yellowing skin/eyes, dark urine, severe abdominal pain.,Avoid alcohol completely while on this medication.,If you miss a dose, take it as soon as you remember unless it's almost time for next dose; do not double dose.,Use effective contraception during treatment and for 30 days after stopping.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOVUNA vs ARAKODA, answered by our medical review team.
SOVUNA is a Antimalarial that works by SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOVUNA and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOVUNA is: 400 mg orally once daily with food.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOVUNA and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOVUNA is classified as Category C. Based on animal studies, SOVUNA (antiviral agent) is associated with increased fetal loss and skeletal anomalies at maternal toxic doses in rodents and rabbits. In humans, data are. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.